Mechanistic characterization of oscillatory patterns in unperturbed tumor growth dynamics: The interplay between cancer cells and components of tumor microenvironment

PLoS Comput Biol. 2023 Oct 4;19(10):e1011507. doi: 10.1371/journal.pcbi.1011507. eCollection 2023 Oct.

Abstract

Mathematical modeling of unperturbed and perturbed tumor growth dynamics (TGD) in preclinical experiments provides an opportunity to establish translational frameworks. The most commonly used unperturbed tumor growth models (i.e. linear, exponential, Gompertz and Simeoni) describe a monotonic increase and although they capture the mean trend of the data reasonably well, systematic model misspecifications can be identified. This represents an opportunity to investigate possible underlying mechanisms controlling tumor growth dynamics through a mathematical framework. The overall goal of this work is to develop a data-driven semi-mechanistic model describing non-monotonic tumor growth in untreated mice. For this purpose, longitudinal tumor volume profiles from different tumor types and cell lines were pooled together and analyzed using the population approach. After characterizing the oscillatory patterns (oscillator half-periods between 8-11 days) and confirming that they were systematically observed across the different preclinical experiments available (p<10-9), a tumor growth model was built including the interplay between resources (i.e. oxygen or nutrients), angiogenesis and cancer cells. The new structure, in addition to improving the model diagnostic compared to the previously used tumor growth models (i.e. AIC reduction of 71.48 and absence of autocorrelation in the residuals (p>0.05)), allows the evaluation of the different oncologic treatments in a mechanistic way. Drug effects can potentially, be included in relevant processes taking place during tumor growth. In brief, the new model, in addition to describing non-monotonic tumor growth and the interaction between biological factors of the tumor microenvironment, can be used to explore different drug scenarios in monotherapy or combination during preclinical drug development.

MeSH terms

  • Animals
  • Cell Line, Tumor
  • Cell Proliferation
  • Mice
  • Models, Biological*
  • Models, Theoretical
  • Neoplasms*
  • Tumor Microenvironment

Grants and funding

JB acknowledges partial financial support from research project with Ref. PID2020-116927RB-C22 from the State Research Agency, Ministry of Economy and Competitivity (Spain).The other authors did not receive any specific funding for this work. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.